Dan Sotirescu - WellSpan Health

Dr. Dan Sotirescu

Claim this profile

Ephrata Cancer Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
28 drugs studied

Area of expertise

1Lung Cancer
Dan Sotirescu has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Non-Small Cell Lung Cancer
Dan Sotirescu has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive

Affiliated Hospitals

Image of trial facility.
Ephrata Cancer Center
Image of trial facility.
Adams Cancer Center

Clinical Trials Dan Sotirescu is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting4 awards Phase 318 criteria

More about Dan Sotirescu

Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Dan Sotirescu has experience with
  • Carboplatin
  • Pembrolizumab
  • Leucovorin Calcium
  • Fluorouracil
  • Irinotecan Hydrochloride
  • Pemetrexed

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Dan Sotirescu specialize in?
Is Dan Sotirescu currently recruiting for clinical trials?
Are there any treatments that Dan Sotirescu has studied deeply?
What is the best way to schedule an appointment with Dan Sotirescu?
What is the office address of Dan Sotirescu?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security